Figure 3.

The four components of the Comprehensive in vitro Proarrhythmia Assay (CiPA). Illustration of the four components of the CiPA initiative. First, drug effects on multiple ion channel currents are assessed. Second, a proarrhythmic score is computed using an in silico model of the human ventricular cardiomyocyte, which integrates the individual ion channel effects assessed in the first component. The third component is a confirmatory in vitro study using human stem cell‐derived ventricular cardiomyocytes. The goal of component four is to use human phase I ECG data to determine if there are unexpected ion channel effects in humans compared to preclinical ion channel data.60